![Yoshitomo Hamuro](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historial de carrera de Yoshitomo Hamuro
Antiguos cargos conocidos de Yoshitomo Hamuro.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
University of California San Diego | Corporate Officer/Principal | - | - |
ExSAR Corp.
![]() ExSAR Corp. Pharmaceuticals: MajorHealth Technology ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases. | Director Técnico/Científico/I+D | 01/01/2002 | - |
Formación de Yoshitomo Hamuro.
University of Pittsburgh | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Consumer Services | 3 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
ExSAR Corp.
![]() ExSAR Corp. Pharmaceuticals: MajorHealth Technology ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases. | Health Technology |
- Bolsa de valores
- Insiders
- Yoshitomo Hamuro
- Experiencia